
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

April 8, 2020

Commission File Number: 001 - 38178

Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)

**Sydmarken 11
2860 Søborg (Copenhagen)
Denmark**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated April 8, 2020, confirming receipt of information on transactions in the Company's shares or related securities by persons discharging managerial responsibilities and/or their closely associated persons.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S

By: /s/ Matthew Dallas

Name: Matthew Dallas

Title: Chief Financial Officer

Date: April 8, 2020

EXHIBIT INDEX

Exhibit No.	Description
<u>99.1</u>	<u>Company announcement dated April 8, 2020</u>
<u>99.2</u>	<u>Notification of sale of shares: A. Steensberg 2020Apr02</u>
<u>99.3</u>	<u>Notification of sale of shares: A. Steensberg 2020Apr03</u>
<u>99.4</u>	<u>Notification of sale of shares: A. Steensberg 2020Apr06</u>



Company announcement – No. 18 / 2020

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, April 8, 2020 – Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

For further information, please contact:

Zealand Pharma Investor Relations

+45 50 60 38 00 investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication
lpm@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand's current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand's portfolio also includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.



Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name	Adam Steensberg						
2.	Reason for the notification							
a)	Position/status	EVP, Chief Medical and Development Officer in Zealand Pharma A/S						
b)	Initial notification/Amendment	Initial notification						
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	Zealand Pharma A/S, CVR-no. 20045078						
b)	LEI ¹	549300ITBB1ULBL4CZ12						
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument	Shares						
	Identification code	DK0060257814						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>DKK 216,3</td><td>96</td></tr> <tr> <td></td><td></td></tr> </tbody> </table>	Price(s)	Volume(s)	DKK 216,3	96		
Price(s)	Volume(s)							
DKK 216,3	96							
d)	Aggregated information - Aggregated volume - Price	DKK 20.762,41						
e)	Date of the transaction	02 April 2020						
f)	Place of the transaction	Nasdaq Copenhagen A/S						



Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name	Adam Steensberg						
2.	Reason for the notification							
a)	Position/status	EVP, Chief Medical and Development Officer in Zealand Pharma A/S						
b)	Initial notification/Amendment	Initial notification						
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	Zealand Pharma A/S, CVR-no. 20045078						
b)	LEI ¹	549300ITBB1ULBL4CZ12						
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument	Shares						
	Identification code	DK0060257814						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>DKK 215,9</td><td>18.158</td></tr> <tr> <td></td><td></td></tr> </tbody> </table>	Price(s)	Volume(s)	DKK 215,9	18.158		
Price(s)	Volume(s)							
DKK 215,9	18.158							
d)	Aggregated information - Aggregated volume - Price	DKK 3.920.584,57						
e)	Date of the transaction	03 April 2020						
f)	Place of the transaction	Nasdaq Copenhagen A/S						



Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name	Adam Steensberg						
2.	Reason for the notification							
a)	Position/status	EVP, Chief Medical and Development Officer in Zealand Pharma A/S						
b)	Initial notification/Amendment	Initial notification						
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	Zealand Pharma A/S, CVR-no. 20045078						
b)	LEI ¹	549300ITBB1ULBL4CZ12						
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument	Shares						
	Identification code	DK0060257814						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>DKK 219,7</td><td>26.764</td></tr> <tr> <td></td><td></td></tr> </tbody> </table>	Price(s)	Volume(s)	DKK 219,7	26.764		
Price(s)	Volume(s)							
DKK 219,7	26.764							
d)	Aggregated information - Aggregated volume - Price	DKK 5.881.311,67						
e)	Date of the transaction	06 April 2020						
f)	Place of the transaction	Nasdaq Copenhagen A/S						